HealthCare Global Enterprises reported a 14.5% rise in consolidated revenue to Rs 2,545.41 crore for FY26. While core revenue grew, net profit for owners dipped to Rs 13.76 crore due to impairment losses from the Milann fertility business divestment. The company also announced its 28th AGM for September 18, 2026, and the launch of a new 132-bed cancer hospital in Bengaluru.
HealthCare Global FY26 Financials and Strategic Shift
Consolidated revenue rose 14.5% to Rs 2,545.41 crore; Net profit attributable to owners declined to Rs 13.76 crore.
Reader Takeaway: Revenue grew on strong patient volumes, but one-time divestment costs pressured the bottom line for the fiscal year.
What just happened
HealthCare Global Enterprises released its FY26 annual report alongside the notice for its 28th AGM, scheduled for September 18, 2026. The company successfully executed a strategic pivot by divesting its fertility business, BACC HealthCare (Milann), to concentrate on its core oncology operations. Simultaneously, it expanded its footprint by commissioning a 132-bed cancer hospital in Hebbal, Bengaluru, featuring advanced radiation therapy technology.
Why this matters
The topline growth of 14.5% reflects healthy operational momentum and increased patient traction. However, the drop in consolidated profit—from Rs 44.41 crore in the previous year to Rs 13.76 crore—highlights the financial impact of the Milann exit and new labor code implementation costs. Investors should view this as a transition year where short-term profitability was sacrificed for long-term strategic alignment.
What changes now
The management is sharpening its focus on oncology. With the divestment of non-core segments complete, the company aims to scale its hospital network more efficiently. Shareholders will also vote on a six-month extension for a consultancy agreement with a related party, Mrs. Anjali Ajaikumar Rossi, at an annualized fee of Rs 1.50 crore.
Risks to watch
Profitability metrics remain a primary concern. Investors need to monitor whether the Hebbal facility can ramp up occupancy quickly to offset the recent impairment losses. Additionally, any further unexpected costs related to regulatory changes could impact margins in the coming quarters.
What to track next
Watch for the management commentary during the AGM regarding the transition to an oncology-pure play and the timeline for stabilization of the new Bengaluru facility.